Heska Corporation and Intervet announced that Intervet has licensed worldwide rights (outside of Canada and South Africa) to patents, trademarks and know-how for Heska's Flu Avert I.N. vaccine.

The agreement includes an up-front fee as well as various other milestone and royalty payments. In the U.S., Intervet will sell Flu Avert I.N. vaccine manufactured at Heska's Des Moines production facility for at least the next three years. Thereafter, Intervet will be free to manufacture on its own.

"We are pleased to license Flu Avert I.N. equine influenza vaccine", said Klaus Olbers, President of Intervet Inc. "Flu Avert I.N. is the world's first intranasal flu vaccine for horses and is an important addition to our broad portfolio of industry leading equine products," Olbers added.

"This agreement represents a strategic decision on our part to focus our resources on healthcare products for dogs and cats, the largest segments of the companion animal market," commented Robert Grieve, Chairman and CEO of Heska. "We are confident our equine users will continue to be well served by Intervet's sales and marketing strength and continued investment in equine health."